Taking down the talking cure

Review of The Therapy Industry: the Irresistible Rise of the Talking Cure, and Why it Doesn’t Work By Paul Moloney, Pluto Press, 2013 Everyone sings the praises of talking therapy these days. A myriad of therapies, each with their own logic and rationale and a technical sounding acronym, claim to cure an increasingly diverse range…

NICE guidelines for bipolar disorder- a missed opportunity

There are some things to applaud about the recently released update of the NICE bipolar guidelines (1,2), not least the recognition that the diagnosis has been inappropriately applied to children with behavioural problems. Hopefully this will help curtail the worrying trend of using toxic bipolar drugs in this age group. As usual, however, the Guidelines…

Continuing the antidepressant debate: the clinical (ir)relevance of drug-placebo differences

German psychiatrist, Stefan Leucht and colleagues, have produced another really important paper (1). The results indicate that the small differences usually found between antidepressants and placebo are far below the sort of differences that would be clinically detectable or meaningful. Leucht et al have conducted the first thorough, systematic attempt to provide some empirical evidence…

‘Psychiatric prejudice’- a new way of silencing criticism

‘Psychiatric prejudice’ is a term being bandied about these days, mainly by aggrieved psychiatrists who feel that psychiatry is not being given equal status with other medical specialities. Ordinary people, other doctors and medical students are all prejudiced because they do not appreciate that psychiatry is a proper medical activity, and critics of psychiatry are…

‘Angels and demons’: the politics of psychoactive drugs

The FIAT (Financial Incentives for Adherence Trial) study, published last year, highlights the paradoxical nature of our current attitude to the use mind-altering drugs. In this randomised controlled trial people with ‘psychotic disorders’ were paid £15 a time to take an injection of an ‘antipsychotic’ drug (1). The payment increased rates of compliance only marginally,…